Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes

Bibliography

• Crespin SR, Greenough WB, Steinberg D. Stimulation of insulin secretion by infusion of free fatty acids. J Clin Invest 1969;48:1934-43
   PubMed Web of Science ®Google Scholar
• Costanzi S, Neumann S, Gershengorn MC. Seven transmembranespanning receptors for free fatty acids as therapeutic targets for diabetes mellitus: pharmacological, phylogenetic, and drug discovery aspects. J Biol Chem 2008;283:16269-73
   PubMed Web of Science ®Google Scholar
• Hirasawa A, Hara T, Katsuma S, et al. Free fatty acid receptors and drug discovery. Biol Pharm Bull 2008;31:1847-51
   PubMed Web of Science ®Google Scholar
• Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003;422:173-76
   PubMed Web of Science ®Google Scholar
• Briscoe CP, Tadayyon M, Andrews JL, et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 2003;278:11303-11
   PubMed Web of Science ®Google Scholar
• Kotarsky K, Nilsson NE, Flodgren E, et al. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem Biophys Res Commun 2003;301:406-10
   PubMed Web of Science ®Google Scholar
• Itoh Y, Hinuma S. GPR40, a free fatty acid receptor on pancreatic beta cells, regulates insulin secretion. Hepatol Res 2005;33:171-73
   PubMed Web of Science ®Google Scholar
• Salehi A, Flodgren E, Nilsson NE, et al. Free fatty acid receptor 1 (FFA(1) R/GPR40) and its involvement in fatty-acid-stimulated insulin secretion. Cell Tissue Res 2005;322:207-15
   PubMed Web of Science ®Google Scholar
• Las G, Mayorek N, Dickstein K, et al. Modulation of insulin secretion by fatty acyl analogs. Diabetes 2006;55:3478-85
   PubMed Web of Science ®Google Scholar
• Madiraju SRM, Poitout V. G Protein-coupled receptors and insulin secretion: 119 and counting. Endocrinology 2007;148:2598-600
   PubMed Web of Science ®Google Scholar
• Rayasam GV, Tulasi VK, Davis JA, et al. Fatty acid receptors as new therapeutic targets for diabetes. Expert Opin Ther Targets 2007;11:661-71
   PubMed Web of Science ®Google Scholar
• Milligan G, Stoddart LA, Brown AJ. G protein-coupled receptors for free fatty acids. Cell Signal 2006;18:1360-65
   PubMed Web of Science ®Google Scholar
• Latour MG, Alquier T, Oseid E, et al. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 2007;56:1087-95
   PubMed Web of Science ®Google Scholar
• Shapiro H, Shachar S, Sekler I, et al. Role of GPR40 in fatty acid action on the β–cell line INS-1E. Biochem Biophys Res Commun 2005;335:97-104
   PubMed Web of Science ®Google Scholar
• Winzell MS, Ahren B. G-protein-coupled receptors and islet function- Implications for treatment of type 2 diabetes. Pharmacol Therapeut 2007;116:437-48
   PubMed Web of Science ®Google Scholar
• Im D-S. Discovery of new G protein-coupled receptors for lipid mediators. J Lipid Res 2004;45:410-18
   PubMed Web of Science ®Google Scholar
• Poul EL, Loison C, Struyf S, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 2003;278:25481-89
   PubMed Web of Science ®Google Scholar
• Brown AJ, Goldsworthy SM, Barnes AA, et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003;278:11312-19
   PubMed Web of Science ®Google Scholar
• Poitout V. The ins and outs of fatty acids on the pancreatic β–cell. Trends Endocrinol Metabol 2003;14:201-03
   PubMed Web of Science ®Google Scholar
• Schnell S, Schaefer M, Schofla C. Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from β-cells through activation of GPR40. Mol Cell Endocrinol 2007;263:173-80
   PubMed Web of Science ®Google Scholar
• Steneberg P, Rubins N, Bartoov-Shifman R, et al. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metabol 2005;1:245-58
   PubMed Web of Science ®Google Scholar
• Kroeze WK, Sheffler DJ, Roth BL. G-protein-coupled receptors at a glance. J Cell Sci 2003;116:4867-69
   PubMed Web of Science ®Google Scholar
• Kostenis E. A glance at G-protein-coupled receptors for lipid mediators: a growing receptor family with remarkably diverse ligands. Pharmacol Ther 2004;102:243-57
   PubMed Web of Science ®Google Scholar
• Database of the IUPHAR Committee on Receptor Nomenclature and Drug Classification. Available from: http://www.iuphar-db.org
   Google Scholar
• Kebede M, Alquier T, Latour GM, et al. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high fat feeding. Diabetes 2008;57:2432-37
   PubMed Web of Science ®Google Scholar
• Lan H, Hoos LM, Liu L, et al. Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 2008;57:2999-3006
   PubMed Web of Science ®Google Scholar
• Bjenning C, Al-shamma H, Thomsen W, et al. G protein-coupled receptors as therapeutic targets for obesity and type 2 diabetes. Curr Opin Invest Drugs 2004;5:1051-62
   PubMedGoogle Scholar
• Stoddart LA. Investigation of the function, pharmacology and oligomerisation of GPR40, GPR41 and GPR43. PhD. Thesis, Institute of Biomedical and Life Science, University of Glasgow; 2007
   Google Scholar
• Lee DK, George SR, O'dow BF. Continued discovery of ligands for G protein-coupled receptors. Life Sci 2003;74:293-97
   PubMed Web of Science ®Google Scholar
• Mckeown SC, Corbett DF, Goetz AS, et al. Solid phase synthesis and SAR of small molecule agonists for the GPR40 receptor. Bioorg Med Chem Lett 2007;17:1584-89
   PubMed Web of Science ®Google Scholar
• Garrido DM, Corbett DF, Dwornik KA, et al. Synthesis and activity of small molecule GPR40 agonists. Bioorg Med Chem Lett 2006;16:1840-45
   PubMed Web of Science ®Google Scholar
• Briscoe CP, Peat AJ, Mckeown SC, et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Brit J Pharmacol 2006;148:619-28
   PubMed Web of Science ®Google Scholar
• Sum CS, Tikhonova IG, Neumann S, et al. Identification of residues important for agonist recognition and activation in GPR40. J Biol Chem 2007;282:29248-55
   PubMed Web of Science ®Google Scholar
• Tikhonova IG, Sum CS, Neumann S, et al. Bidirectional, iterative approach to the structural delineation of the functional chemoprint in GPR40 for agonist recognition. J Med Chem 2007;50:2981-89
   PubMed Web of Science ®Google Scholar
• Tikhonova IG, Sum CS, Neumann S, et al. Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. J Med Chem 2008;51:625-33
   PubMed Web of Science ®Google Scholar
• Corbett DF, Dwornik KA, Garrido DM, et al. Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40. GlaxoSmithKline plc. WO2005051890; 2005
   Google Scholar
• Yasuma T, Negoro N, Sasaki S. Aminophenylpropanoic acid derivative. Takeda Pharmaceuticals. EP1726580; 2005
   Google Scholar
• Yasuma T, Negoro N, Sasaki S. Aminophenylpropanoic acid derivative. Takeda Pharmaceuticals. WO2005087710; 2005a
   Google Scholar
• Negoro K, Ohnuki K, Kurosaki T, et al. Carboxylic acid derivative. Astellas Pharma Inc. WO2008066097; 2008
   Google Scholar
• Song F, Lu S, Gunnet J, et al. Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists. J Med Chem 2007;50:2807-17
   PubMed Web of Science ®Google Scholar
• Kuo GH, Song F, Gunnet J, et al. GPR40 agonists. Johnson and Johnson. US2008176912; 2008
   Google Scholar
• Min GE, Jiafang HE, Lau FWY, et al. Antidiabetic bicyclic compounds. Merck & Co., Inc. WO2007136572; 2007
   Google Scholar
• Min GE, Jiafang HE, Lau FWY, et al. Antidiabetic bicyclic compounds. Merck & Co., Inc., WO2007136573; 2007a
   Google Scholar
• Min GE, Jiafang HE, Lau FWY, et al. Antidiabetic bicyclic compounds. Merck & Co., Inc., US2007265332; 2007b
   Google Scholar
• Min GE, Lin S, Walsh S, et al. Antidiabetic bicyclic compounds. Merck & Co., Inc. WO2008054675; 2008
   Google Scholar
• Akerman M, Houze J, Lin DCH, et al. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders. Amgen Inc. WO2005086661; 2005
   Google Scholar
• Houze J, Liu J, Ma Z, et al. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders. Amgen Inc. US2006270724; 2006
   Google Scholar
• Houze J, Liu J, Ma Z, et al. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders. Amgen Inc., WO2006127503; 2006a
   Google Scholar
• Sharma R, Akerman M, Cardozo M, et al. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders. Amgen Inc. WO2007106469; 2007
   Google Scholar
• Beck H, Dransfield P, Fu Z, et al. Heterocyclic GPR40 modulators. Amgen Inc., WO2008030520; 2008a
   Google Scholar
• Akerman M, Brown S, Houze JB, et al. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders. Amgen Inc. WO2007033002; 2007
   Google Scholar
• Akerman M, Brown S, Houze JB, et al. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders. Amgen Inc., US2007066647; 2007a
   Google Scholar
• Beck H, Dransfield P, Fu Z, et al. Heterocyclic GPR40 Modulators. Amgen Inc. US20080090840; 2008
   Google Scholar
• Brown S, Dransfield P, Houze JB, et al. Benzo-fused compounds for use in treating metabolic disorders. Amgen Inc. WO2008030618; 2008
   Google Scholar
• Fukatsu K, Sasaki S, Hinuma S, et al. Receptor function controlling agent. Takeda Pharmaceuticals. WO2004041266; 2004
   Google Scholar
• Fukatsu K, Sasaki S, Hinuma S, et al. Receptor function controlling agent. Takeda Pharmaceuticals. EP1559422; 2005
   Google Scholar
• Fukatsu K, Sasaki S, Hinuma S, et al. Receptor function regulator. Takeda Pharmaceuticals. JP2005015461; 2005
   Google Scholar
• Hinuma S, Yasuma T, Harada M, et al. Receptor function regulator. Takeda Pharmaceuticals. CA2505322; 2005
   Google Scholar
• Yasuma T, Kitamura S, Sakai N. Alkoxyphenylpropanoic acid derivatives. Takeda Pharmaceuticals. WO2005095338; 2005
   Google Scholar
• Yasuma T, Sasaki S, Sakai N. Phenylpropanoic acid derivatives. Takeda Pharmaceuticals. WO2005063725; 2005
   Google Scholar
• Yasuma T, Sasaki S, Sakai N. Phenylpropanoic acid derivatives. Takeda Pharmaceuticals. US2007155808; 2007
   Google Scholar
• Yasuma T, Sasaki S, Sakai N. Phenylpropanoic acid derivatives. Takeda Pharmaceuticals. EP1698624; 2006
   Google Scholar
• Yasuma T, Negoro N, Fukatsu K. Condensed ring compound. Takeda Pharmaceuticals. US2006258722; 2006
   Google Scholar
• Yasuma T, Negoro N, Fukatsu K. Condensed ring compound. Takeda Pharmaceuticals. JP2005343792; 2005
   Google Scholar
• Yasuma T, Negoro N, Fukatsu K. Condensed ring compound. Takeda Pharmaceuticals. WO2004106276; 2004
   Google Scholar
• Suzuki N, Suzuki M, Asakawa T, et al. Remedy for diabetes. Takeda Pharmaceuticals. WO2006011615; 2006
   Google Scholar
• Suzuki N, Suzuki M, Asakawa T, et al. Therapeutic agent for diabetes. Takeda Pharmaceuticals. JP2007284350; 2007
   Google Scholar
• Yasuma T, Negoro N. Cyclopropanecarboxylic acid compound. Takeda Pharmaceuticals. WO2007013689; 2007
   Google Scholar
• Yasuma T, Negoro N, Yamashita M, et al. Fused cyclic compounds. Takeda Pharmaceuticals. WO2008001931; 2008
   Google Scholar
• Yasuma T, Kitamura S, Negoro N. 3-(4-Benzyloxyphenyl) propanoic acid derivatives. Wenderoth, Lind & ponack. US2007149608; 2007
   Google Scholar
• Yasuma T, Kitamura S, Negoro N. 3-(4-Benzyloxyphenyl) propanoic acid derivatives. Wenderoth, Lind & ponack. JP2006083154; 2006
   Google Scholar
• Yasuma T, Kitamura S, Negoro N. 3-(4-Benzyloxyphenyl) propanoic acid derivatives. Takeda Pharmaceuticals. WO2005063729; 2005
   Google Scholar
• Yasuma T, Kitamura S, Sakai N. Alkoxyphenylpropanoic Acid Derivatives. Wenderoth, Lind & ponack. US2007213364; 2007
   Google Scholar
• Defossa E, Goerlitzer J, Klabunde T, et al. 4,5-Diphenyl-pyrimidinyl-oxy or -mercapto substituted carboxylic acids, method for the production and use thereof as medicaments. Sanofi-aventis. WO2007131619; 2007
   Google Scholar
• Defossa E, Goerlitzer J, Klabunde T, et al. 4,5-Diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments. Sanofi-aventis. WO2007131620; 2007
   Google Scholar
• Defossa E, Goerlitzer J, Klabunde T, et al. 4,5-Diphenyl-pyrimidinyl substituted carboxylic acids, method for the production and use thereof as medicaments. Sanofi-aventis. WO2007131621; 2007
   Google Scholar
• Gardner OS, Dewar BJ, Graves LM. Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling. Mol Pharmacol 2005;68:933-41
   PubMed Web of Science ®Google Scholar
• Stoddart LA, Brown AJ, Milligan G. Uncovering the pharmacology of the G protein-coupled receptor GPR40: High apparent constitutive activity in guanosine 5′-O-(3-[35S]-thio)triphosphate binding studies reflects binding of an endogenous agonist. Mol Pharmacol 2007;71:994-1005
   PubMed Web of Science ®Google Scholar
• Tan CP, Feng Y, Zhou Y-P, et al. Selective small-molecule agonists of G protein–coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 2008;57:2211-19
   PubMed Web of Science ®Google Scholar
• Ge M, Yang L, Zhou C, et al. Antidiabetic bicyclic compounds. Merck & Co, Inc. WO2006083612; 2006
   Google Scholar
• Ge M, Yang L, Zhou C, et al. Antidiabetic bicyclic compounds. Merck & Co, Inc. EP1843766; 2007
   Google Scholar
• Ge M, Yang L, Zhou C, et al. Antidiabetic bicyclic compounds. Merck & Co, Inc. US2008090865; 2008
   Google Scholar
• Ge M, Yang L, Zhou C, et al. Antidiabetic bicyclic compounds. Merck & Co., Inc., WO2006083781; 2006
   Google Scholar
• Ge M, Yang L, Zhou C, et al. Antidiabetic bicyclic compounds. Merck & Co., Inc., EP1846379; 2006b
   Google Scholar
• Ge M, Lin S, Yang L, et al. Antidiabetic bicyclic compounds. Merck & Co, Inc. WO2008054674;2008
   Google Scholar
• Owman C, Olde B, Roeme D, et al. Therapeutic modulators of GPR40. Heptahelix AB. WO2007049050; 2007
   Google Scholar
• Tsujimoto G, Hirasawa A. Agonist of G protein coupled receptor, and medicine. Pharma Frontier KK. JP2008001690; 2008
   Google Scholar
• Negoro K, Iwasaki F, Ohnuki K, et al. Oxadiazolidinedione compound. Astellas Pharma Inc. WO2007123225; 2007
   Google Scholar
• Christiansen E, Urban C, Merten N, et al. Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA1/GPR40), a potential target for the treatment of type II diabetes. J Med Chem 2008;51:7061-64
   PubMed Web of Science ®Google Scholar
• Bharate SB, Rodge A, Joshi RK, et al. Discovery of diacylphloroglucinols as a new class of GPR40 (FFAR1) agonists. Bioorg Med Chem Lett 2008;18:6357-61
   PubMed Web of Science ®Google Scholar
• Defossa E, Follmann M, Klabunde T, et al. Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments. Sanofi-aventis. DE102006021878; 2007
   Google Scholar
• Defossa E, Follmann M, Klabunde T, et al. Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments. Sanofi-aventis. WO2007131622; 2007a
   Google Scholar
• Hamamura K, Sasaki S, Amano Y, et al. Furan or thiophene derivative and its pharmaceutical use. Takeda Pharmaceuticals. JP2005035966; 2007
   Google Scholar
• Hamamura K, Sasaki S, Amano Y, et al. Furan or thiophene derivative and its medicinal use thereof. Takeda Pharmaceuticals. WO2004022551; 2007a
   Google Scholar
• Covington DK, Briscoe CA, Brown AJ, et al. The G-protein-coupled receptor 40 family (GPR40–GPR43) and its role in nutrient sensing. Biochem Soc Trans 2006;34:770-73
   PubMed Web of Science ®Google Scholar
• Itoh F, Sasaka S, Miyazaki J, et al. Receptor function regulating agent. Takeda Pharmaceuticals. US2008021069; 2007
   Google Scholar
• Itoh F, Sasaka S, Miyazaki J, et al. Receptor function regulating agent. Takeda Pharmaceuticals. WO2006038738; 2007a
   Google Scholar
• Itoh F, Sasaka S, Miyazaki J, et al. Receptor function regulating agent. Takeda Pharmaceuticals. EP1810677; 2007b
   Google Scholar
• Dobbins RL, Chester MW, Stevenson BE, et al. A fatty acid-dependent step is critically important for both glucose and non-glucose-stimulated insulin secretion. J Clin Invest 1998;101:2370-76
   PubMed Web of Science ®Google Scholar
• Kashyap S, Belfort R, Gastaldelli A, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003;52:2461-74
   PubMed Web of Science ®Google Scholar
• Mason TM, Tracy G, Tchipashvili V, et al. Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. Diabetes 1999;48:524-30
   Google Scholar
• Flodgren E, Olde B, Meideute-Abaraviciene S, et al. GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem Biphys Res Commun 2007;354:240-45
   PubMed Web of Science ®Google Scholar
• Doshi LS, Brahma MK, Sayyed SG, et al. Acute administration of GPR40 receptor agonist potentiates glucose stimulated insulin secretion in vivo in rat. Metabolism 2008; In press
   Google Scholar
• Edfalk S, Steneberg P, Edlund H. GPR40 is expressed in enteroendocrine cells and mediatesfree fatty acid stimulation of incretin secretion. Diabetes 2008;57:2280-87
   PubMed Web of Science ®Google Scholar
• Adachi T, Tanaka T, Takemoto K, et al. Free fatty acids administered into the colon promote the secretion of glucagons like peptide-1 and insulin. Biochem Biophys Res Commun 2006;340:332-27
   PubMed Web of Science ®Google Scholar
• Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci 2000;66:91-103
   PubMed Web of Science ®Google Scholar